Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide. Originally considered to be restricted to humans, it is now clear that HEV and HEV-like viruses have several animal reservoirs with complex ecology and genetic diversity, as exemplified by the recent discovery of HEV in dromedaries, a previously underestimated reservoir of zoonotic viruses prior to the emergence of Middle East Respiratory Syndrome coronavirus. Zoonotic foodborne transmission from pigs and feral animals such as wild boar is of increasing importance in the rapidly industrializing countries of the Asia Pacific region. Such zoonotic hepatitis E infection has particular relevance to the increasing population living with immunosuppression, due to the risk of chronic hepatitis E in these patients. Fortunately, major strides have been made recently in the management of chronic hepatitis E patients. Furthermore, an effective vaccine is also available that promises better control of hepatitis E burden in the near future. This review highlights these major recent developments in the epidemiology, treatment, and prevention of hepatitis E.

Basic virology and epidemiology of hepatitis E virus

Hepatitis E virus (HEV) is a member of the genus *Hepevirus* within the family *Hepeviridae*. It is a nonenveloped virus measuring approximately 27–34 nm in diameter. The single stranded, positive sense RNA genome of HEV comprises three open reading frames (ORFs). ORF1 encodes nonstructural proteins including methyltransferase,
protease, helicase, and RNA-dependent RNA polymerase. ORF2 encodes the capsid protein, which enables virus cell entry and contains the targets for neutralizing antibodies. ORF3 encodes a phosphorylated protein that is important for virus release.1

It is estimated that there are 20 million hepatitis E infections worldwide every year, making it the most common cause of acute viral hepatitis in most regions including Hong Kong.2,3 HEV infection is silent in most individuals and when symptomatic, usually produces a self-limiting icteric illness. However, progression to severe fulminant liver failure may occur in certain high-risk groups, such as pregnant women and elderly patients with underlying liver disease. Although there is only one serotype, four major HEV genotypes capable of infecting humans are currently recognized. HEV genotypes 1 and 2 are only found in humans and account for most of the hepatitis E in the developing world where transmission occurs by the fecal-orlux via contaminated waterways. HEV genotypes 3 and 4 are found in swine and other animals across the world, sporadically infecting humans in industrialized countries via foodborne routes. Human-to-human spread in developed countries is limited to blood-borne transmission via blood products derived from viremic donors. In addition to these genotypes of clinical importance, several novel HEV-like viruses have been discovered in a variety of animal specimens, similar to each other in overall genomic organization but differing in terms of the total genome length and position of ORF3 with respect to the ORF1/2 junction.4

Expanding range of animal reservoirs of HEV: More than just pigs

Domestic pigs are the most important reservoirs of the HEV genotypes that are capable of infecting humans. HEV3 was first isolated from swine specimens in the United States in 1997, when it was also discovered that large proportions of herds across the North American Midwest were seropositive against HEV, a finding echoed by studies on swine populations across the world.5,6 Another genotype of clinical importance, HEV4, was identified from pigs in Taiwan.7 This genotype has subsequently been found to be enzootic in China and Japan; it has also recently been reported in swine populations and autochthonous human infections in Europe.8–11 HEV infection generally affects young pigs and is subclinical. Given the high fecal viral loads and prolonged periods of virus shedding in stool, transmission between pigs is likely to be fecal-oral.12

HEV genotypes 3 and 4 have also been found in a number of other animal species, most significantly in animals hunted for game meat such as deer and wild boar.13–15 Closely related strains have also been detected in mongooses, rabbits, and rats.16–22 In addition, the discovery of a number of novel HEV-like viruses from an increasing variety of animals has brought light to the immense ecological diversity of HEVs and has resulted in a call for an expansion and reorganization of the current classification system of the Hepeviridae family.23–38 As an example, our recent work on dromedary camels has not only led to the discovery of a novel genotype of HEV, but is also the first description of different genomic features in different strains of the same HEV.38 The geographical distribution of terrestrial animal reservoirs of HEV is summarized in (Table 1) and (Fig. 1).

Accumulating evidence for zoonotic transmission to humans

Zoonotic transmission of HEV3 and HEV4 to humans is well established by various lines of evidence. Increased HEV seroprevalence in swine handlers compared to the general public provides indirect evidence for subclinical infection due to contact with infected animals.39,40 Nonhuman pri-mates have been successfully infected by both HEV geno-types 3 and 4 in experimental settings, proving the feasibility of zoonotic infection.3,41 Epidemiological studies from outbreaks and case series show that a history of consumption of uncooked deer, wild boar meat, and shellfish is a risk factor for acquiring hepatitis E.42–44 The foodborne zoonotic source hypothesis is further supported by the high sequence similarity of HEV gene sequences from patients with autochthonous hepatitis E and animal sources

| HEV genotype | Natural host | Geographical distribution | Transmission route in human infection |
|--------------|--------------|----------------------------|---------------------------------------|
| Genotype 1   | Humans       | Asia, Africa               | Human-to-human, waterborne outbreaks  |
| Genotype 2   | Humans       | Africa, Mexico             | Human-to-human, waterborne outbreaks  |
| Genotype 3   | Humans, domestic pigs, wild boar, mongoose, deer | Worldwide distribution in pigs, human infection in Europe, North/South America, East Asia, and Australia | Zoonotic foodborne blood products |
| Genotype 4   | Humans, domestic pigs, wild boar | China, Japan | Zoonotic foodborne |
| Rabbit HEV   | Rabbits      | China, North America, Europe | Some evidence for zoonotic transmission, pending definitive confirmation |
| Rat HEV      | Rats         | Asia, Europe, North America | N/A a |
| Camel HEV    | Camels       | Middle East                | N/A a |
| Avian HEV    | Chickens, turkeys | Worldwide               | N/A a |

a Not applicable as zoonotic potential unknown.
in the same region. HEV3 and HEV4 RNA are frequently detected in meat products originating from pigs and feral animals that are sold for human consumption. In a local study in Hong Kong, 31% of pig liver samples were positive for HEV RNA and the sequences were identical to human cases in the region, highlighting the risk of acquiring hepatitis E from consumption of foods such as pig liver congee, which is a common delicacy in the region. Homogenates of such contaminated meat have been successfully used to infect pigs, demonstrating that the HEV RNA forms a part of the fully viable infectious particles. Deserving special mention is the recent detection of HEV3 RNA from shellfish, which may be an emerging, indirect vehicle for zoonotic transmission and highlights the health risks of consuming undercooked bivalves that filter feed in waterbeds supplied by runoff contaminated with swine excreta or viscera. Due to rapid industrialization and improvement in sanitary conditions in many parts of East Asia, zoonotic HEV transmission is assuming an increasing importance with a resultant genotype switch from HEV1 to HEV3 or HEV4. In other developing countries in Asia, although HEV genotypes are frequently detected in pigs and other animals, most human disease still occurs by person–person spread of HEV1. However, even in such settings, zoonotic transmission may account for some hepatitis E cases. Although rat, rabbit, and mongoose populations are known to harbor HEV strains that are closely related to human pathogenic HEV strains, their role in causing zoonotic human hepatitis E is unclear at this stage.

The potential of rats to harbor infectious HEV is a particular concern due to their close proximity to urban human dwellings. As for the possible role of dromedary camel HEV, although a study has shown that HEV is the commonest cause of acute hepatitis in Dubai, no sequence information from the HEV strains involved is available. Further genomic studies on HEV from Dubai patients should reveal the importance of dromedaries as the possible source of HEV in the Middle East.

**Clinical significance of animal HEV reservoirs**

The ubiquitous presence of HEV3 and HEV4 in various animal reservoirs has a direct impact on clinical practice. Patients presenting with acute hepatitis should be asked about recent consumption of undercooked pork, shellfish, or game meat. Contact with swine or their effluent should be explored. Transfusion of blood products is also a potential route of acquisition of hepatitis E. Patients reporting such exposures should be tested for HEV immunoglobulin M or RNA. Besides expediting diagnosis, such epidemiological clues could also enable treatment of certain groups of patients at risk of chronic hepatitis E infection (see below) and facilitate outbreak investigation. Although most zoonotic HEV cases are sporadic, point source foodborne HEV outbreaks are well documented.
Acquisition of HEV through the use of porcine derived medical products such as heparin, insulin, or coagulation factors has never been convincingly demonstrated, but remains a theoretical possibility given the ubiquity of HEV in swine populations.  

The zoonotic potential of the increasing number of newly discovered HEV genotypes is unclear at this stage. These viruses demonstrate high host specificity: interspecies transmission of non-3, non-4 HEVs is seldom achieved in experimental infection settings and also appears to be rare in nature. However, this possibility should always be considered in patients presenting with acute hepatitis after contact with exotic animals or consumption of their meat. If the novel HEV has highly divergent nucleotide sequences, the performance of conventional serological diagnostic tests is uncertain. However, the use of panhepeviral consensus primers will still enable such cases to be recognized. The increasing use of unbiased next generation sequencing on randomly amplified nucleic acid extracts as part of metagenomic analysis of patient specimens may also enable detection of novel HEVs in clinical settings.

The understanding of reservoirs and routes of transmission enables the institution of specific preventive measures. Public health education on the avoidance of undercooked meat and seafood remains the single most important preventative measure; there is evidence to suggest that boiling meat or stir-frying at high heat for 5 minutes can inactivate infectious viral particles. Patients who face immunosuppression should be reminded of such methods. Vaccination is an attractive alternative, but its cost-effectiveness for population-wide hepatitis E in this group. Vaccination is an attractive alternative, but its cost-effectiveness for population-wide usage remains to be evaluated. HEV control at the level of animal husbandry remains to be assessed; measures such as housing swine in barrier conditions and regular screening of HEV RNA have been proposed for herds raised to provide xenotransplants and other medical products. However, such methods are likely to be inhumane and commercially impractical for swine raised for the food industry. With increasing public recognition of the risk of foodborne hepatitis E, HEV control solutions at other steps in the meat production chain must be sought.

HEV infection in immunocompromised patients

Hepatitis E was previously considered to be a cause of acute hepatitis with no progression to chronic carriage. However, this perception changed with the publication of a case series of 14 solid organ transplant recipients with acute autochthonous HEV3 infection in southern France. The authors showed that eight of the 14 patients progressed to chronic hepatitis characterized by mild derangement in liver enzymes, persistently detectable HEV RNA in serum and stool for > 3 months, delayed/absent HEV seroconversion, and histological features of chronic viral hepatitis such as dense lymphocytic perportal infiltrates with piecemeal necrosis. Chronic HEV carriage has been described in liver, kidney, pancreas, heart-lung, and stem cell transplant recipients. Autochthonous hepatitis E infection in the posttransplant setting appears to be uncommon. Screening studies of HEV RNA in the sera of liver transplant recipients showed a hepatitis E infection prevalence of < 1% in Europe. However, approximately half of all patients with acute autochthonous hepatitis E in the posttransplant period progress to chronic infection; conversion rates of 80% have been reported in one French case series. The prevalence of chronic hepatitis E among transplant recipients in Asian countries is unknown.

Alarming, a significant proportion of these chronic HEV carriers rapidly progress to cirrhosis and portal hypertension. The inability to clear HEV viremia is directly related to the degree of immunosuppression of these patients at the time of infection. Therefore, infections that occur shortly after transplantation, rejection episodes, or when the patient has low total lymphocyte counts are more likely to progress to chronic infection. The use of tacrolimus (as opposed to ciclosporin) is also known to be a risk factor for chronic HEV in posttransplant patients. HEV immunoglobulin G seropositivity prior to transplantation does not exclude these patients from reinfection post-transplantation and such reinfections have been reported to progress to chronic infection. Reactivation of endogenous HEV post-stem cell transplantation has also been reported.

Chronic HEV infection has also rarely been described in two other immunocompromised patient groups — HIV carriers and patients with hematological malignancy. From the little data available, it appears that chronic HEV coinfection in some HIV positive patients with low CD4 counts (< 200 cells/µL) produces severe liver injury with rapid progression to cirrhosis. Awareness and recognition of this entity is crucial as specific therapy is available to halt disease progression (see below). The exact prevalence of chronic HEV carriage in the HIV carrying population remains to be delineated. The description of chronic HEV in patients with leukemia and lymphoma on chemotherapy is limited to a few case reports. Although this may reflect that the condition is uncommon, underdiagnosis due to lack of awareness among clinicians is a possibility.

There are many causes of liver function derangement in transplant patients including drugs, cytomegalovirus disease, graft rejection, graft versus host disease, etc. Hepatitis E is often not considered in the list of differentials by physicians. Even when hepatitis E is considered, an inappropriate diagnostic strategy may result in the diagnosis being missed. This is because enzyme immunoassay based tests that are frequently used for exclusion of acute hepatitis E in immunocompetent patients are unreliable for diagnosis in immunocompromised patients, due to their variable timeframe to seroconversion. HEV reverse transcriptase-polymerase chain reaction of blood and stool specimens should be considered in any immunocompromised patient with deranged liver function tests of unknown etiology. Although only three groups of immunocompromised patients have been identified to be at risk for chronic hepatitis E so far, clinicians may also face this condition in other patients with profound chronic immunosuppression — especially autoimmune conditions such as systemic lupus erythematosus.

Most cases of chronic HEV infection are related to the consumption of undercooked pork or, in some cases, mussels and game meat. Blood product transfusions are a potentially important mode of acquisition as well. In the
United Kingdom, it has recently been estimated that one in 2848 donors have hepatitis E viremia at the time of donation.\textsuperscript{80} This was associated with acute hepatitis as well as persistent infection in some immunocompromised recipients. This raises questions about the need for screening blood products for HEV RNA prior to transfusion to groups at risk of persistent infection. Given the asymptomatic or mild course of the majority of cases of hepatitis E infection in the general population, instituting generalized screening of blood products for HEV prior to transfusion requires a thorough cost-effectiveness analysis. Transmission of HEV via an infected liver graft has been reported.\textsuperscript{81}

Most cases of chronic HEV are reported from Europe and the Americas. Unsurprisingly, nearly all the HEV isolates from these patients belong to genotype 3, the predominating HEV genotype in these areas. The first case of HEV4 chronic infection has only recently been described in a patient from China.\textsuperscript{77} The potential of HEV1 and HEV2 to establish chronic infection in human beings is unknown. With wider availability of molecular diagnosis and sequencing, close surveillance of transplant recipients and HIV positive patients in developing countries should be undertaken to define this risk.

A comparative summary of clinical features and diagnosis of acute and chronic forms of hepatitis E is presented in (Table 2).

### Treatment of HEV infections

Immunocompromised patients diagnosed with hepatitis E should be closely followed up with regular monitoring of blood HEV RNA viral load, liver function tests, and liver stiffness. Delay in the management of persistent viremia should be minimized due to the potentially rapid onset of irreversible liver injury. Reduction in immunosuppression should be considered for patients with persistent HEV viremia for > 3 months. If viremia still persists or if immunosuppression is otherwise essential, specific antiviral treatment or immunomodulation should be considered. Immunomodulation with pegylated interferon has been used successfully in liver transplant recipients with chronic hepatitis E, but its wider use in the transplant setting is discouraged due to the risk of graft rejection.\textsuperscript{82} A 24-week course of pegylated interferon has been used to treat HIV positive patients with chronic HEV.\textsuperscript{72}

There is accumulating evidence for the use of the guanosine analogue ribavirin in persistently viremic patients who fail a trial of immunosuppression reduction.\textsuperscript{83–86} In a recent case series involving 59 post-solid organ transplant patients with chronic hepatitis E, ribavirin monotherapy for a median of 3 months resulted in a sustained virological response (defined in the study as clearance of viremia for 25 months after treatment) in 78% of patients.\textsuperscript{85} Liver function tests normalized in all of these patients. Some patients who developed recurrent viremia achieved sustained virological response after retreatment with ribavirin for 6 months. Anemia was the most important treatment related side effect. Six months of ribavirin monotherapy has also been used anecdotally in HIV patients with chronic HEV with clearance of viremia and improvement in liver stiffness and liver function tests.\textsuperscript{74} The effect of antiretroviral therapy in facilitating clearance of HEV viremia is unknown.

Patients with delayed diagnosis who present with liver cirrhosis may be considered for liver transplantation. However, reactivation of HEV after liver transplantation for chronic hepatitis E has been described; this can result in recurrent hepatitis of the liver graft.\textsuperscript{69} Therefore, virological clearance with ribavirin should be considered before considering transplantation for this patient group. The management of immunocompromised patients diagnosed with hepatitis E is summarized in (Fig. 2).

Ribavirin has anecdotally been used for treatment of acute hepatitis E in both immunocompetent and HIV positive patients.\textsuperscript{86–89} It is unclear whether the patients recovered due to ribavirin use or as a result of the natural course of the disease. It is generally accepted that the acute hepatitis following HEV infection arises from immunopathology rather than a direct viral cytopathic effect. Therefore, the biological role of ribavirin in modulating disease progress is unclear. Controlled trials are required to define the role of ribavirin in the treatment of patients with acute hepatitis E. Ribavirin prophylaxis has been described for postexposure prophylaxis of some viral hemorrhagic fever viruses.\textsuperscript{90} This raises the intriguing possibility of ribavirin for postexposure prophylaxis in sequestered outbreak settings, such as refugee camps and military

### Table 2  Clinical spectrum and management of hepatitis E.

| Risk factors                                      | Chronic hepatitis E                                      |
|--------------------------------------------------|---------------------------------------------------------|
| Travel to HEV endemic areas                      | Patients with acute hepatitis E who are:                |
| Consumption of undercooked pork, deer, wild boar,| Solid organ or hematopoietic stem cell transplant       |
| bivalves                                          | recipients                                              |
| Recently received blood products                  | Receiving chemotheraphy for hematological malignancy    |
| Severe disease in pregnancy, elderly, and patients| HIV positive with CD4 counts <200/μL                    |
| with underlying liver disease                     | Acute phase often asymptomatic, progression to cirrhosis and portal hypertension over months-years |
| Icteric illness, usually self-limiting, but may progress to fulminant hepatitis in high-risk patients | HEV RT-PCR of stool/plasma, serology is not reliable    |

Clinical features

| Diagnosis | HEV IgM, may consider HEV RT-PCR of stool/plasma for diagnosis/genotyping |
|-----------|--------------------------------------------------------------------------|

Treatment

| Treatment | Supportive | Refer to Fig. 2 for treatment algorithm |

HEV = hepatitis E virus; IgM = immunoglobulin M; RT-PCR = reverse transcriptase-polymerase chain reaction.
Figure 2  Management overview of hepatitis E in immunocompromised patients. a In HIV positive patients, may alternatively consider 6 month course of pegylated interferon therapy ± ribavirin. b Evidence based on 1 case series and several case reports. c Evidence based on 1 case series. HEV = hepatitis E virus; RT-PCR = reverse transcriptase-polymerase chain reaction.
encampments, to suppress initial viral replication. However, ribavirin is strictly contraindicated in pregnant women, limiting its use in an important high-risk group. Therefore, hepatitis E vaccination still remains the most important prospect for disease prevention in such settings (see below).

Hepatitis E vaccination

HEV 239 (Hecolin), a recombinant bacterially expressed polypeptide vaccine based on a 26 kDa segment of HEV genotype 1 ORF2, was licensed in China in 2011. The polypeptide takes the form of a virus-like particle with surface presentation of immunodominant epitopes for optimal immunogenicity. In a Phase III clinical trial involving 112,604 participants from 11 townships in China, healthy adults were randomized to receive either three doses of HEV 239 (at 0 months, 1 month, and 6 months) or placebo (hepatitis B vaccine). They were followed up for 13 months after receiving the third dose. No participants in the HEV 239 vaccine arm, who had received at least two doses, developed clinical hepatitis E during the follow up period. Vaccine efficacy at 19 months after one dose of HEV 239 was estimated to be 95.5% (95% Confidence Interval 66.3–99.4). In a subsequent analysis on the vaccinated population, protection extends to 2 years after vaccination and is independent of hepatitis B carrier status. The vaccine was well tolerated and also appears to be safe in pregnancy on preliminary analysis. Interestingly, the majority of patients in the placebo group who developed clinical hepatitis E had genotype 4 HEV RNA on sequencing. This supports previous animal studies that found this genotype 1 based vaccine to be highly cross protective against HEV4, a zoonotic genotype. This is a significant finding that encourages trial of the vaccine in areas with HEV3 predominance. While the vaccine appears highly promising, questions remain about the duration of protection, efficacy in outbreak settings, immunogenicity in young children, immunogenicity against HEV3, and efficacy in immunocompromised patients. A Phase IV trial, currently in progress, involving individuals above the age of 65 years, will address the effectiveness of the vaccine in elderly recipients, a group at risk for severe zoonotic HEV infection. The HEV 239 vaccine has also been shown to be highly immunogenic in rabbits, conferring protection against both HEV4 and rabbit HEV. If vaccination is found to be effective in blocking transmission in swine populations, animal vaccination may be an effective intervention to reduce zoonotic hepatitis E in developed countries.

The HEV vaccine is another capsid antigen based purified polypeptide vaccine produced in insect cell lines infected by a recombinant baculovirus vector. This vaccine was found to be safe and effective in a Phase II trial involving HEV seronegative army recruits in Nepal, where HEV1 predominates. Further assessment of this vaccine is pending.

In the light of the above evidence, the HEV 239 vaccine may be offered to healthy adults at risk of acquiring hepatitis E—a population that includes residents and travelers to HEV1 and HEV4 endemic areas. Vaccine efficacy in outbreak settings, HEV3 endemic areas, pediatric populations, and immunocompromised patients require further study.

Conclusion: New answers, new questions

With a better understanding of HEV come new challenges. While improvement of sanitation facilities is the clear (if difficult to achieve) solution for hepatitis E control in resource-poor settings, the roadmap for autochthonous foodborne disease control in developed countries is less clear. Effective HEV control in meat production chains will take a major industry initiative, but may be the only way forward for sustained control of autochthonous hepatitis E. The need to screen blood products for HEV RNA is currently under debate and is generating considerable public interest. Further refinement of treatment paradigms of acute and chronic hepatitis E is required. The genetic basis for reduced viral ribavirin susceptibility should be defined for patients who fail ribavirin therapy. Alternatives such as favipiravir should be explored in case of ribavirin treatment failure in chronic hepatitis E patients. Finally, political will and resource mobilization is required to export the effective and safe vaccine to areas where it is most required. Ongoing characterization of novel animal HEV genotypes is important due to the possibility of such viruses undertaking a species jump to cause human infections in the future.

References

1. Yamada K, Takahashi M, Hoshino Y, Takahashi H, Ichiyama K, Nagashima S, et al. ORF3 protein of hepatitis E virus is essential for virion release from infected cells. J Gen Virol 2009;90:1880–91.
2. World Health Organization. Global prevalence of hepatitis E: a systematic review. Available at: http://whqlibdoc.who.int/hq/2010/WHO_IVB_10.14_eng.pdf. [accessed 24.08.14].
3. Lo M, Chan WK, Lin AW, Wong KH. Surveillance of viral hepatitis in Hong Kong—2012 Update Report. http://www.info.gov.hk/hepatitis/doc/hepsurv12.pdf. [accessed 26.08.14].
4. Johne R, Dremsek P, Reetz J, Heckel G, Hess M, Ulrich RG. Hepeviridae: An expanding family of vertebrate viruses. Infect Genet Evol 2014;27:212–29.
5. Meng XJ, Purcell RH, Halbur PG, Lehman JR, Webb DM, Tsareva TS, et al. A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci USA 1997;94:9860–5.
6. Okamoto H. Genetic variability and evolution of hepatitis E virus. Virus Res 2007;127:216–28.
7. Hsieh SY, Meng XJ, Wu YH, Liu ST, Tam AW, Lin DY, et al. Identity of a novel swine hepatitis E virus in Taiwan forming a monophyletic group with Taiwan isolates of human hepatitis E virus. J Clin Microbiol 1999;37:3828–34.
8. Takahashi M, Nishizawa T, Miyajima H, Gotanda Y, Iita T, Tsuda F, et al. Swine hepatitis E virus strains in Japan form four phylogenetic clusters comparable with those of Japanese isolates of human hepatitis E virus. J Gen Virol 2003;84:851–2.
9. Liu P, Li L, Wang L, Bu Q, Fu H, Han J, et al. Phylogenetic analysis of 626 hepatitis E virus (HEV) isolates from humans and animals in China (1986-2011) showing genotype diversity and zoonotic transmission. Infect Genet Evol 2012;12(12):428–34.
10. Hakze-van der Honing RW, can Coillie E, Antonis AF, van der Poel WH. First isolation of hepatitis E virus genotype 4 in
Europe through swine surveillance in the Netherlands and Belgium. PLoS One 2011;6:e22673. http://www.ncbi.nlm.nih.gov/pubmed/21829641.

11. Colson P, Romanet P, Moal V, Borentain P, Purgus R, Benzzech A, et al. Autochthonous infections with hepatitis E virus genotype 4, France. Emerg Infect Dis 2012;18:1361–4.

12. Kasornkdukka C, Guenette DK, Huang FF, Thomas PJ, Meng XJ, Halbur PG. Routes of transmission of swine hepatitis E virus in pigs. J Clin Microbiol 2004;42:5047–52.

13. Sonoda H, Abe M, Sugimoto T, Sato Y, Bando M, Fukui E, et al. Prevalence of hepatitis E virus (HEV) infection in wild boars and deer and genetic identification of a genotype 3 HEV from a boar in Japan. J Clin Microbiol 2004;42:5371–4.

14. Wiratsudakul A, Sariya L, Prompiram P, Tantawet S, Suraruangchai D, Sedwisai P, et al. Detection and phylogenetic characterization of hepatitis E virus genotype 3 in a captive wild boar in Thailand. J Zoo Wildl Med 2012;43:640–4.

15. Okano H, Nakano T, Sugimoto K, Takahashi K, Nagashima S, Takahashi M, et al. High genomic similarity between European type hepatitis E virus subgenotype 3e strains isolates from an acute hepatitis patient and a wild boar in Mie, Japan. Hepatol Res 2014;44:694–9.

16. Lhomme S, Dubois M, Abravanel F, Top S, Bertagnoli S, Guerin JL, et al. Risk of zoonotic transmission of HEV from rabbits. J Clin Virol 2013;58:257–62.

17. He J, Innis BL, Shrestha MP, Clayson ET, Scott RM, Linthicum KJ, et al. Evidence that rodents are a reservoir of hepatitis E virus for humans in Nepal. J Clin Microbiol 2002;40:4493–8.

18. Johne R, Plenge-Bönig A, Hess M, Ulrich RG, Reetz J, Schielke A. Detection of a novel hepatitis E-like virus in faeces of wild rats using a nested broad-spectrum RT-PCR. J Gen Virol 2010;91:750–8.

19. Lack JB, Volk K. Van Den Bussche RA. Hepatitis E virus genotype 3 in wild rats, United States. Emerg Infect Dis 2012;18:1268–73.

20. Mulyanto, Depamede SN, Srisath M, Takahashi M, Nagashima S, Jirintai S, et al. Frequent detection and characterization of hepatitis E virus variants in wild rats (Rattus rattus) in Indonesia. Arch Virol 2013;158:87–96.

21. Li W, Guan D, Su J, Takeda N, Wakiita T, Li TC, et al. High prevalence of rat hepatitis E virus in wild rats in China. Vet Microbiol 2013;165:275–80.

22. Nidaira M, Takahashi K, Ogura G, Taira K, Okano S, Kudaka J, et al. Detection and phylogenetic analysis of hepatitis E viruses from mongooses in Okinawa, Japan. J Vet Med Sci 2012;74:1665–8.

23. Smith DB, Simmonds P, Jameel S, Emerson SU, Harrison TJ, Meng XJ, et al. Consensus proposals for classification of the family Hepeviridae. J Gen Virol 2014;95:2223–32.

24. de Paula VS, Wiele M, Mbunkah AH, Daniel AM, Kingsley MT, Schmidt-Chanasit J. Hepatitis E virus genotype 3 strains in domestic pigs, Cameroon. Emerg Infect Dis 2013;19:666–8.

25. Kalba M, Colson P, Musongela JP, Tshiolo L, Davoust B. Detection of hepatitis E virus genotype 3 in a farm pig in Kinshasa (Democratic Republic of the Congo). Infect Genet Evol 2010;10:154–7.

26. Drexler JF, Seelen A, Corman VM, Fumie Tateno A, Cottontail V, Melim Zerbinati R, et al. Bats worldwide carry hepatitis E virus-related viruses that form a putative novel genus within the family Hepeviridae. J Virol 2012;86:9134–47.

27. Raj VS, Smits SL, Pas SD, Provacia LB, Moorman-Roest H, Osterhaus AD, et al. Novel hepatitis E virus in ferrets, the Netherlands. Emerg Infect Dis 2012;18:1369–70.

28. Kwon HM, Sung HW, Meng XJ. Serological prevalence, genetic identification, and characterization of the first strains of avian hepatitis E virus from chickens in Korea. Virus Genes 2012;45:237–45.

29. Hsu IW, Tsai HJ. Avian hepatitis E virus in chickens, Taiwan, 2013. Emerg Infect Dis 2014;20:149–51.

30. Zhao Q, Zhou EM, Dong SW, Qiu HK, Zhang L, Hu SB. Analysis of avian hepatitis E virus from chickens, China. Emerg Infect Dis 2010;16:1469–72.

31. Bilic I, Jaskuliska B, Basic A, Morrow CJ, Hess M. Sequence analysis and comparison of avian hepatitis E viruses from Australia and Europe indicate the existence of different genotypes. J Gen Virol 2009;90:863–73.

32. Agunos AC, Yoo D, Youssef SA, Ran D, Binnington B, Hunter DB. Avian hepatitis E virus in an outbreak of hepatitis-splenomegaly syndrome and fatty liver haemorrhagic syndrome in two foaxed-fed layer flocks in Ontario. Avian Pathol 2006;35:404–12.

33. Haqshenas G, Shivarprasad HL, Woolcock PR, Read DH, Meng XJ. Genetic identification and characterization of a novel virus related to human hepatitis E virus from chickens with hepatitis-splenomegaly syndrome in the United States. J Gen Virol 2001;82:2449–62.

34. Spreij NG, Nikonova ZB, Zinyakov NG. Avian hepatitis E virus identified in Russian chicken flocks exhibits high genetic divergence based on the ORF2 capsid gene. Avian Pathol 2012;41:459–63.

35. Lin J, Norder H, Uhlhorn H, Belák S, Widen F. Novel hepatitis E-like virus found in Swedish moose. J Gen Virol 2014;95:557–70.

36. Medrano C, Boadelia M, Barrios H, Cantú A, García Z, de la Fuente J, et al. Zoonotic pathogens among white-tailed deer, northern Mexico, 2004–2009. Emerg Infect Dis 2012;18:1372–4.

37. Rutjes SA, Lodder-Verschoor F, Lodder WJ, van der Giessen J, Reesink H, Bouwknegt M, et al. Seroprevalence and molecular detection of hepatitis E virus in wild boar and red deer in The Netherlands. J Virol Methods 2010;168:197–206.

38. Woo PC, Lau SK, Teng JL, Tsang AK, Joseph M, Wong EY, et al. New hepatitis E virus genotype in camels, the Middle East. Emerg Infect Dis 2014;20:1044–8.

39. Lee JT, Shao PL, Chang LY, Xia NS, Chen PJ, Lu CY, et al. Seroprevalence of hepatitis E virus infection among swine farmers and the general population in rural Taiwan. PLoS One 2013;8:e67180. http://www.ncbi.nlm.nih.gov/pubmed/23840620.

40. Liang H, Su S, Deng S, Gu H, Ji F, Wang L, et al. The prevalence of hepatitis E virus infections among swine farmers and the general population in Guangdong Province, China. PLoS One 2014;9:e88106. http://www.ncbi.nlm.nih.gov/pubmed/24520348.

41. Meng XJ. Swine hepatitis E virus: cross-species infection and risk in xenotransplantation. Curr Top Microbiol Immunol 2003;278:185–216.

42. Tei S, Kitajima N, Ohara S, Inoue Y, Miki M, Yamatanai T, et al. Consumption of uncooked deer meat as a risk factor for hepatitis E virus infection: an age- and sex-matched case-control study. J Med Virol 2004;74:67–70.

43. Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, et al. Autochthonous infections with hepatitis-splenomegaly syndrome in the United States. Emerg Infect Dis 2013;19:67–70.

44. Nishizawa T, Takahashi M, Mizuo H, Miyajima H, Gotanda Y, Okamoto H. Characterization of Japanese swine and human hepatitis E virus isolates of genotype IV with 99% identity over the entire genome. J Gen Virol 2003;84:1245–51.
Recent developments in hepatitis E

46. Li TC, Chijiwa K, Sera N, Ishibashi T, Etoh Y, Shinohara Y, et al. Hepatitis E virus transmission from wild boar meat. Emerg Infect Dis 2005;11:1958–60.
47. Berto A, Martelli F, Grierson S, Banks M. Hepatitis E virus in pork food chain, United Kingdom, 2009-2010. Emerg Infect Dis 2012;18:1358–60.
48. Berto A, Grierson S, Hakze-van der Honing R, Martelli F, Johne R, et al. Hepatitis E virus in pork liver sausage, France. Emerg Infect Dis 2013;19:264–6.
49. Feagins AR, Opriessnig T, Guenette DK, Halbur PG, Meng XJ. Detection and characterization of infectious hepatitis E virus from commercial pig livers sold in local grocery stores in the USA. J Gen Virol 2007;88:912–7.
50. Centre for Food Safety. Food and Environmental Hygiene Department. Hepatitis E virus infection among animals in northern India: an unlikely source of human disease. Emerg Infect Dis 2007;13:260–1.
51. Shukla P, Chauhan UK, Naik S, Anderson D, Aggarwal R. Hepatitis E virus genotype 3 in shellfish, United Kingdom. J Gen Virol 2007;88:912–7.
52. Crossan C, Baker PJ, Craft J, Takeuchi Y, Dalton HR, Scobie L. Hepatitis E virus infection in farmed rabbits and swine in the Eastern Chinese city Lianyungang: Showing no potential interspecies transmission. J Med Virol 2014;86:1898–904.
53. Wibawa ID, Suryadarma IG, Mulyanto, Tsuda F, Matsumoto Y, Abro AH, Abdou AM, Saleh AA, Ustadi AM, Hussaini HS. Hepatitis E: a common cause of acute viral hepatitis. J Pak Med Assoc 2009;59:92–4.
54. Crossan C, Scobie L, Godwin J, Hunter JG, Hawkes T, Dalton HR. Hepatitis E virus and porcine-derived hepaticin. Emerg Infect Dis 2013;19:686–8.
55. Busby SA, Crossan C, Godwin J, Petersen B, Galli C, Cozzi E, et al. Suggestions for the diagnosis and elimination of hepatitis E virus in pigs used for xenotransplantation. Xenotransplantation 2013;20:188–92.
56. Kamar N, Selves J, Mansuy JM, Quezzani L, Peiron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811–7.
57. Versluis J, Pas SD, Agtersch HJ, de Man RA, Maaskant J, Schipper ME, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood 2013;122:1079–86.
58. Halac U, Béland K, Lapierre P, Patey N, Ward P, Brassard J, et al. Cirrhosis due to chronic hepatitis E infection in a child post-bone marrow transplant. J Pediatr 2012;160:871–4.
59. Riezebos-Brilman A, Puchhammer-Stöckl E, van der Weide HY, Haagsma EB, Jaksh P, Beijl EJ, et al. Chronic hepatitis E infection in lung transplant recipients. J Heart Lung Transplant 2013;32:341–6.
60. Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 2008;14:547–53.
61. Haagsma EB, Niesters HG, van den Berg AP, Riezebos-Brilman A, Porte RJ, Vennema H, et al. Prevention of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009;15:1225–8.
62. Pischke S, Suneetha PV, Baechlein C, Barg-Hock H, Heim A, Kamar N, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010;16:74–82.
63. Moal V, Legris T, Burtey S, Morange S, Purgus R, Dussoi B, et al. Infection with hepatitis E virus in kidney transplant recipients in southeastern France. J Med Virol 2013;85:462–71.
64. Abramove J, Colson P. Chronic hepatitis E: a common cause of acute viral hepatitis. J Med Virol 2007;81:699–702.
65. Neukam K, Barreiro P, Macias J, Avellóin A, Cifuentes C, Martín-Carbonero L, et al. Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis 2013;57:465–8.
66. Rajhi H, Gérolami R, Sales C, Moreau J, Colson P. Chronic hepatitis E resolution in a human immunodeficiency virus (HIV)-infected patient treated with ribavirin. Int J Antimicrob Agents 2013;41:959–7.
67. Jaggii Singh GK, Ijaz S, Rockwood N, Farnsworth SP, Devitt E, Atkins M, et al. Chronic hepatitis E as a cause for cryptogenic cirrhosis in HIV. J Infect 2013;66:103–6.
68. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009;361:1025–7.
69. Tapaura A, Shimizu YK, Tanaka T, Kuroda K, Arakawa Y, Takahashi K, et al. Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res 2007;37:113–20.
70. Ollier L, Tielrieu N, Sanderson F, Heudier P, Giordano V, Fuzibet JG, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med 2009;150:430–1.
71. Geng Y, Zhang H, Huang W, J Harrison T, Geng K, Li Z, et al. Persistent hepatitis e virus genotype 4 infection in a child with acute lymphoblastic leukemia. Hepat Mon 2014;14:e15618. http://www.ncbi.nlm.nih.gov.eproyx1.iib.hku/pubmed/24596581.
72. Abramovale F, Chapuy-Regaud S, Lhomme S, Miedouge M, Peron JM, Aalić L, et al. Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. J Clin Virol 2013;58:624–8.
73. Legrand-Abravanel F, Kamar N, Sandres-Saune K, Garrycute C, Dubois M, Mansuy JM, et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis 2010;202:835–44.
74. Hewitt PE, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014;384:1766–73.
75. Schlosser B, Stein A, Neuhaus R, Pahl S, Ramez B, Krüger DH, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol 2012;56:507–12.
76. Kamar N, Roastaing L, Abravanel F, Garrycute C, Esposito L, Cardeau-Desangles I, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 2010;50:e30–3.
83. Kamar N, Rostaing L, Abravanel F, Garrouste C, Lhomme S, Esposito L, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. *Gastroenterology* 2010;139:1612–8.

84. Alric L, Bonnet D, Beynes-Rauzy O, Izopet J, Kamar N. Definitive clearance of a chronic hepatitis E virus infection with ribavirin treatment. *Am J Gastroenterol* 2011;106:1562–3.

85. Kamar N, Izopet J, Tripop S, Bismuth M, Hillaire S, Dumortier J, et al. Ribavirin for chronic hepatitis E virus infection in transplant infection. *N Engl J Med* 2014;370:1111–20.

86. Gerolami R, Borentain P, Raissouni F, Motte A, Solas C, Colson P. Treatment of severe acute hepatitis E by ribavirin. *J Clin Virol* 2011;52:60–2.

87. Goyal R, Kumar A, Panda SK, Paul SB, Acharya SK. Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report. *Antivir Ther* 2012;17:1091–6.

88. Pischke S, Hardtke S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann W, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. *Liver Int* 2013;33:722–6.

89. Robbins A, Lambert D, Ehrhard F, Brodard V, Hentzien M, Lebrun D, et al. Severe acute hepatitis E in an HIV infected patient: Successful treatment with ribavirin. *J Clin Virol* 2014;60:422–3.

90. Guner R, Hasanoglu I, Tasyaran MA, Yaper D, Keske S, Guven T, et al. Is ribavirin prophylaxis effective for nosocomial transmission of Crimean-Congo hemorrhagic fever? *Vector Borne Zoonotic Dis* 2014;14:601–5.

91. Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectiveity on primates. *Vaccine* 2005;23:2893–901.

92. Zhang X, Wei M, Pan H, Lin Z, Wang K, Weng Z, et al. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin®. *Vaccine* 2014;32:4039–50.

93. Wei M, Zhang X, Yu H, Tang ZM, Wang K, Li Z, et al. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes. *Vaccine* 2014;32:2859–65.

94. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomized, double-blind placebo-controlled, phase 3 trial. *Lancet* 2010;376:895–902.

95. Huang SJ, Liu XH, Zhang J, Ng MH. Protective immunity against HEV. *Curr Opin Virol* 2014;5:1–6.

96. Wu T, Huang SJ, Zhu FC, Zhang XF, Ai X, Yan Q, et al. Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults. *Hum Vaccine Immunother* 2013;9:2474–9.

97. Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J, et al. Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. *Hepatology* 2012;55:2038.

98. Phase IV clinical trial of recombinant hepatitis E vaccine. Available at: http://clinicaltrials.gov/show/NCT02189603. [accessed 26.08.14].

99. Liu P, Du RJ, Wang L, Han J, Liu L, Zhang YI, et al. Management of hepatitis E virus (HEV) zoonotic transmission: protection of rabbits against HEV challenge following immunization with HEV 239 vaccine. *PLoS One* 2014;9:e87600. http://www-ncbi-nlm-nih-gov.eproxy2.lib.hku.hk/pubmed/24498149.

100. Shrestha MP, Scott RM, Joshi DM, Mammen Jr MP, Thapa GB, Thapa N, et al. Safety and efficacy of a recombinant hepatitis E vaccine. *N Engl J Med* 2007;356:895–903.